optimal treatment of actinic keratoses
Clicks: 219
ID: 153429
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
219 views
46 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #31 of 40 articles by views in imaging science journal
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Elizabeth E UhlenhakeDepartment of Dermatology, Wayne State University School of Medicine, Detroit, MI, USAAbstract: The most compelling reason and primary goal of treating actinic keratoses is to prevent malignant transformation into invasive squamous cell carcinoma, and although there are well established guidelines outlining treatment modalities and regimens for squamous cell carcinoma, the more commonly encountered precancerous actinic lesions have no such standard. Many options are available with variable success and patient compliance rates. Prevention of these lesions is key, with sun protection being a must in treating aging patients with sun damage as it is never too late to begin protecting the skin.Keywords: actinic keratosis, photodynamic therapy, topical chemotherapy, field therapyA Letter to the Editor has been received and published for this article.
| Reference Key |
ee2013clinicaloptimal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Uhlenhake EE |
| Journal | imaging science journal |
| Year | 2013 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.